Morgan Stanley Reiterates Equal-Weight on Chemours, Maintains $33 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vincent Andrews has reiterated an Equal-Weight rating on Chemours (NYSE:CC) and maintained a $33 price target.
August 04, 2023 | 9:20 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley has reiterated an Equal-Weight rating on Chemours and maintained a $33 price target, indicating a neutral outlook.
The reiteration of an Equal-Weight rating by Morgan Stanley indicates a neutral outlook for Chemours. The maintained price target of $33 suggests that the analyst believes the stock is fairly valued at its current price. This could potentially lead to a stable short-term price movement for Chemours.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100